| Journal | American journal of preventive medicine |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
As more states legalize medical cannabis, there is growing interest in its use in adolescents. This nationally-representative study assesses the prevalence of medically recommended cannabis use in adolescents and associations between medical cannabis use and adverse correlates. Cross-sectional data from the 2021-2023 National Survey on Drug Use and Health were used to identify adolescents aged 12-17 who reported past-year cannabis use. Respondents were asked whether health care professionals recommended any cannabis use. The prevalence of past-year medically recommended and non-medical cannabis use was estimated among all adolescents and differences in sociodemographic factors, cannabis use disorder (CUD), and other substance use between these two groups was estimated. Multivariable-adjusted logistic regression models then assessed the odds of CUD and other substance use, adjusted for sociodemographic factors. Among 3,906 adolescents reporting past-year cannabis use, 183 (5.2% weighted
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
